Collegium Pharmaceutical (COLL) Operating Leases (2019 - 2026)

Collegium Pharmaceutical's Operating Leases history runs 8 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• In Q1 2026, Operating Leases fell 27.16% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $3.8 million (down 27.16% YoY), while the FY2025 annual figure was $4.1 million, down 25.4% from the prior year.
• Operating Leases was $3.8 million for Q1 2026 at Collegium Pharmaceutical, down from $4.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $7.9 million in Q1 2022 to a low of $3.8 million in Q1 2026.
• Historically, Operating Leases has averaged $6.0 million across 5 years, with a median of $5.9 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Operating Leases retreated 7.36% in 2024, then declined 27.16% in 2026.
• A 5-year view of Operating Leases shows it stood at $7.1 million in 2022, then slipped by 13.89% to $6.1 million in 2023, then slipped by 9.55% to $5.5 million in 2024, then retreated by 25.4% to $4.1 million in 2025, then declined by 8.35% to $3.8 million in 2026.
• The last three Operating Leases figures came in at $3.8 million (Q1 2026), $4.1 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.